← Eichor
Study identifier: NCT07384013 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Study Protocol: Impact of Metamizole (Optalgin®) on Anti-Xa Concentrations in Oncology Patients Receiving DOACs

Condition: Oncologic Diseases · Coagulation Defect · Pain Management  ·  Sponsor: Rambam Health Care Campus

PhaseNA
Planned participants30
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Evaluation of the Effect of metamizole (Optalgin®) on Anti-Xa Levels in Oncology Patients Receiving Direct Oral Anticoagulants (DOACs)

This description comes directly from the study's public registry record.

Talk to the study team

Liat Rappaport  ·  +97247776234  ·  o_trials@rambam.health.gov.il

Always discuss trial participation with your own doctor first.

Locations (1)

Rambam Health Care CampusHaifa, IsraelRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07384013